You’re using a public version of DrugPatentWatch with 1 free search available | Register to unlock more free searches. CREATE FREE ACCOUNT

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Last Updated: October 1, 2023

Patent: 8,039,469

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,039,469
Title:Triazine compounds as PI3 kinase and mTOR inhibitors
Abstract: Compounds of formula I ##STR00001## wherein: R.sup.1 is ##STR00002## and R.sup.2, R.sup.4, and R.sup.6-9 are defined herein, and pharmaceutically acceptable salts and esters thereof. These compounds inhibit PI3 kinase and mTOR, and may be used to treat diseases mediated by PI3 kinase and mTOR, such as a variety of cancers. Methods for making and using the compounds of this invention are disclosed. Various compositions containing the compounds of this invention are also disclosed.
Inventor(s): Venkatesan; Aranapakam Mudumbai (Rego Park, NY), Chen; Zecheng (New City, NY), Dehnhardt; Christoph Martin (New York, NY), Santos; Osvaldo dos (Astoria, NY), Santos; Efren Guillermo Delos (Nanuet, NY), Zask; Arie (New York, NY), Verheijen; Jeroen Cunera (Highland Mills, NY), Kaplan; Joshua Aaron (Nyack, NY), Richard; David James (Warwick, NY), Ayral-Kaloustian; Semiramis (Tarrytown, NY), Mansour; Tarek Suhayl (New City, NY), Gopalsamy; Ariamala (Mahwah, NJ), Curran; Kevin Joseph (Congers, NY), Shi; Mengxiao (Eastchester, NY)
Assignee: Wyeth LLC (Madison, NJ)
Application Number:12/470,521
Patent Claims:see list of patent claims

Details for Patent 8,039,469

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Recordati Rare Diseases, Inc. ELSPAR asparaginase For Injection 101063 01/10/1978 ⤷  Try a Trial 2039-02-26
Bayer Healthcare Pharmaceuticals Inc. BETASERON interferon beta-1b For Injection 103471 07/23/1993 ⤷  Try a Trial 2039-02-26
Biogen Inc. AVONEX interferon beta-1a For Injection 103628 05/17/1996 ⤷  Try a Trial 2039-02-26
Biogen Inc. AVONEX interferon beta-1a Injection 103628 05/28/2003 ⤷  Try a Trial 2039-02-26
Biogen Inc. AVONEX interferon beta-1a Injection 103628 02/27/2012 ⤷  Try a Trial 2039-02-26
Emd Serono, Inc. REBIF interferon beta-1a Injection 103780 03/07/2002 ⤷  Try a Trial 2039-02-26
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.